Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 274

Sort by

Sort Order Select

Journal Articles

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Blood (2024) 144 (24): 2490–2502.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study

Alexis Thompson, Ashima Singh, Donna S. Neuberg, Amanda M. Brandow, Allison A. King, Sophie Lanzkron, Emily A. Semmel, Sam Walters, Susan Rogers, Kathleen Hewitt, William A. Wood

Blood (2024) 144 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2024-194157

Published: 2024

Journal Articles

Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2024-203981

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 645.

https://doi.org/10.1182/blood-2024-200167

Published: 2024

Journal Articles

Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN

Shai O. Shimony, Julia Keating, Marlise R. Luskin, Christopher Fay, Florian Renosi, Eric Deconinck, Francine Garnache-Ottou, Donna S. Neuberg, Nicole R. Leboeuf, Andrew A. Lane

Blood (2024) 144 (Supplement 1): 321.

https://doi.org/10.1182/blood-2024-198275

Published: 2024

Journal Articles

Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes

Nicoletta Cieri, Yiren Shao, Kaila Power, Vincent T. Ho, Jonathan Stevens, William J. Lane, Haesook T. Kim, Donna S. Neuberg, Chip Stewart, Gad Getz, Jerome Ritz, Robert J. Soiffer, Catherine J. Wu

Blood (2024) 144 (Supplement 1): 102.

https://doi.org/10.1182/blood-2024-198976

Published: 2024

Journal Articles

Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Blood (2024) 144 (Supplement 1): 926.

https://doi.org/10.1182/blood-2024-199009

Published: 2024

Journal Articles

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul Vedula, Donna S. Neuberg, Marcio Andrade-Campos, Simon Smith, Richard M Stone, Amir T. Fathi, Matthew J. Walter, Timothy Aaron Graubert, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2024-195793

Published: 2024

Journal Articles

The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse

Blood (2024) 144 (Supplement 1): 2711.

https://doi.org/10.1182/blood-2024-200289

Published: 2024

Journal Articles

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2024-210377

Published: 2024

Journal Articles

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Chi-Joan How, Yiwen Liu, Kathleen Gallagher, Emma K Logan, Ann Mullally, Donna S. Neuberg, Thomas Reardon, Alyssa Watson, Daniel J. DeAngelo, Rushad Patell, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6644.

https://doi.org/10.1182/blood-2024-194126

Published: 2024

Journal Articles

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Elisa Ten Hacken, Johan Gustafsson, Chiara Tomasoni, Gabriela Brunsting Hoffmann, Kayla Cruz, Wesley S Lu, Shuqiang Li, Nicholas Haradhvala, Connor Johnson, Stephanie Deng, Xia Bu, Donna S. Neuberg, Othman Al-Sawaf, Barbara F. Eichhorst, Clare Sun, Erin M. Parry, Gordon J. Freeman, Gad Getz, Catherine J. Wu

Blood (2024) 144 (Supplement 1): 761.

https://doi.org/10.1182/blood-2024-201006

Published: 2024

Journal Articles

Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation

Blood (2024) 144 (Supplement 1): 758.

https://doi.org/10.1182/blood-2024-202115

Published: 2024

Journal Articles

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Melissa A. Burns, Yael Flamand, Lynda M. Vrooman, Victoria B. Koch, Yves Theoret, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Donna S. Neuberg, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 307.

https://doi.org/10.1182/blood-2024-207273

Published: 2024

Journal Articles

Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Salma Parvin, Binyamin Knisbacher, Aditi Aryal, Stacey M. Fernandes, Shlomi Medalion, Guy Leib, Johan Gustafsson, Shir Amit, Eden C Meidan, Nadav Y Klein, Savion Nafussy, Donna S. Neuberg, Catherine J. Wu, Jennifer R. Brown, Gad Getz, Anthony G. Letai

Blood (2024) 144 (Supplement 1): 76.

https://doi.org/10.1182/blood-2024-201594

Published: 2024

Journal Articles

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Blood (2024) 144 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2024-200876

Published: 2024

Journal Articles

The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3233.

https://doi.org/10.1182/blood-2024-199916

Published: 2024

Journal Articles

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2024-198284

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study

Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma

Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN

Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes

Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only